Browse studies

Find your next paid study

27,306 recruiting studies available now

A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, th…

Healthy VolunteersAlzheimer DiseaseAmyloid+1 more

Estimated

~$500 – $11,250

Actual pay is set by the research site.

Eli Lilly and CompanyNCT07787182

Observational

Supporting Older Adults Remotely (SOAR): Protocol for a Type 1 Hybrid Effectiveness-Implementation Randomized Controlled Trial of a Certified Older Adult Peer Specialist Intervention

The Supporting Older Adults Remotely (SOAR) study is a randomized controlled trial evaluating a 12-week, telephone-delivered peer support intervention for adul…

Severe Mental Illness

Estimated

~$10 – $750

Actual pay is set by the research site.

Dartmouth-Hitchcock Medical CenterNCT07878169

Phase 3

An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma

This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called car…

Relapsed and/or Refractory Multiple Myeloma (RRMM)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT07222761

Phase 1

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help de…

Neoplasms, Solid TumorBreast Neoplasms, Triple-NegativeSquamous Cell Carcinoma of Skin+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Onchilles Pharma IncNCT07339176

Phase 3

A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants With Solid and Hematologic Cancers (ROXI-CAT-II)

This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on pa…

Venous Thromboembolism (VTE)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT07493304

Phase 2

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Ca…

Pancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Verastem, Inc.NCT07644559

Identification Of Lung Cancer In Never-Smoking Individuals Using A Non-Invasive Volatile Organic Compound (VOCs) Biological Platform With Urine Specimens

The goal of this observational study is to learn whether a urine-based test that measures volatile organic compounds (VOCs) can help detect lung cancer in peop…

Lung Cancer

Estimated

~$10 – $750

Actual pay is set by the research site.

Thomas Jefferson UniversityNCT07871656

Observational

Support Towards Addiction Recovery for Individuals With Criminal Legal System Involvement: The STAR Project

The goal of this clinical trial is to determine whether a new, paired coaching intervention improves outcomes for individuals with criminal legal system involv…

Addiction

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Martha TillsonNCT07596251

Phase 2

Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the s…

Acute LeukemiaSevere Aplastic AnemiaNon-hodgkin Lymphoma+6 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Mitchell CairoNCT04099966

Phase 2

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to- Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid

The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have f…

Colitis, Ulcerative

Estimated

~$75 – $3,000

Actual pay is set by the research site.

MRM Health NVNCT07296315

Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy

Background: Turner Syndrome, galactosemia, and premature ovarian insufficiency are all conditions that may make it very hard or impossible for a person to bec…

Turner SyndromePost-menarcheal AdolescentsOvarian Disfunction+3 more

Estimated

~$10 – $675

Actual pay is set by the research site.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT04948658

Phase 2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membr…

Focal Segmental GlomerulosclerosisMinimal Change DiseaseMembranous Nephropathy

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Human Genome Research Institute (NHGRI)NCT06664814